Cumberland Partners Ltd Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cumberland Partners Ltd lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 117.6% during the 3rd quarter, Holdings Channel reports. The firm owned 15,450 shares of the company’s stock after buying an additional 8,350 shares during the period. Cumberland Partners Ltd’s holdings in Johnson & Johnson were worth $2,504,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Meridian Financial Partners LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $1,626,000. Lmcg Investments LLC grew its holdings in Johnson & Johnson by 32.7% during the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after acquiring an additional 21,471 shares in the last quarter. Cooper Haims Advisors LLC raised its holdings in shares of Johnson & Johnson by 6.4% in the 1st quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock valued at $531,000 after purchasing an additional 201 shares in the last quarter. Trajan Wealth LLC grew its stake in shares of Johnson & Johnson by 11.3% during the third quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock worth $5,347,000 after purchasing an additional 3,341 shares in the last quarter. Finally, Entropy Technologies LP increased its holdings in Johnson & Johnson by 127.5% in the first quarter. Entropy Technologies LP now owns 37,592 shares of the company’s stock valued at $5,947,000 after buying an additional 21,071 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. The Goldman Sachs Group lowered their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Trading Down 1.5 %

Shares of Johnson & Johnson stock opened at $152.64 on Wednesday. The company has a 50-day moving average of $162.39 and a two-hundred day moving average of $155.97. The stock has a market cap of $367.50 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 2.75 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.66 EPS. On average, research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.25%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.